Antithrombin activity

Company	Reagent	Link to information	Remarks
Chromogenix	Coamatic Antithrombin		Reagent: Lyophilized Method: Chromogenic Assay principle: Anti Xa
Chromogenix	Coamatic LR Antithrombin		Reagent: Liquid Method: Chromogenic Assay principle: Anti Xa
Helena Biosciences	Antithrombin Xa		Reagent: Lyophilized Method: Chromogenic Assay principle: Anti Xa
Hyphen BioMed	Biophen Antithrombin	Hyphen Biophen Antithrombin	Reagent: Lyophilized Method: Chromogenic Assay principle: Anti Xa Interferences: No interference of heparin, heparin Cofactor II, alpha-2-macroglobulin or alpha1-Antitrypsin.No significant interference for haemoglobin < 2.5 mg/ml, and bilirubin < 0.1 mg/ml
Hyphen BioMed	Biophen AT anti-(h)-Xa LRT	Hyphen Biophen AT anti-(h)-Xa LRT	Reagent: Liquid Method: Chromogenic Assay principle: Anti Xa Interferences: No interference of heparin, heparin Cofactor II, alpha-2-macroglobulin or alpha1-Antitrypsin.No significant interference for haemoglobin < 2.5 mg/ml, and bilirubin < 0.1 mg/ml
Hyphen BioMed	Biophen AT (anti-lla)	Hyphen Biophen AT (anti-lla)	Reagent: Lyophilized Method: Chromogenic Assay principle: Anti IIa Interferences: No interference of heparin (UFH, LMWH) at usual therapeutic doses
Hyphen BioMed	Biophen AT (LRT)	Hyphen Biophen AT (LRT)	Reagent: Liquid Method: Chromogenic Assay principle: Anti Xa Interferences: No interference of heparin, heparin Cofactor II, alpha-2-macroglobulin or alpha1-Antitrypsin.No significant interference for haemoglobin < 2.5 mg/ml, and bilirubin < 0.1 mg/ml
Nordic Biomarker	MRX Antithrombin		Reagent: Liquid Method: Chromogenic Assay principle: Anti Xa
Renam	Reachrom-ATIII		Method: Chromogenic
Renam	Reaclot-ATIII		Method: Clotting
Roche	AT	Roche AT	Reagent: Liquid Method: Chromogenic Assay principle: anti IIa
Siemens Healthineers	Berichrom Antithrombin III	Siemens Berichrom Anthitrombin III	Reagent: Lyophilized Method: Chromogenic Assay principle: Anti Xa Inteferences: Therapeutic doses of hirudin or other direct thrombin inhibitors will cause erroneously increased antithrombin III activity.
Siemens Healthineers	Innovance Antithrombin	Siemens Innovance Antithrombin	Reagent: Liquid Method: Chromogenic Assay principle: Anti Xa Interferences: No interference of heparin < 2 U/ml, heparin cofactor II < 400 mg/L, hirudin < 5 mg/L, therapeutic doses of oral direct factor Xa inhibitors may cause erroneously increased antithrombin activity.
Stago	STA-Stachrom AT III	Stago STA-Stachrom AT III	Reagent: Lyophilized Method: Chromogenic Assay principle: Anti IIa Interferences: No interferences of therapeutic doses of heparin, hemoglobin < 7 g/l, bilirubin < 200 mg/l, triglycerides < 7.6 g/l, thrombin inhibitors may lead to an over-estimation of the AT level.
Stago, Tcoag	TriniCHROM Antithrombin lla	Stago TriniCHROM Antitrombin IIa	Method: Chromogenic Assay principle: Anti IIa Interferences: Interference of heparin cofactor
Stago, Tcoag	TriniCHROM Antithrombin Xa	Stago TriniCHROM Antitrombin Xa	Method: Chromogenic Assay principle: Anti Xa Interferences: No interference of heparin cofactor II
Technoclone	Technochrom ATIII kit	Technoclone Technochrom ATIII kit	Method: Chromogenic Assay principle: Anti IIa
Technoclone	Technochrom ATIII manual method kit	Technoclone Technochrom ATIII manual method kit	Method: Chromogenic Assay principle: Anti IIa
Werfen	HemosIL Antithrombin	Werfen HemosIL Antithrombin	Reagent: Lyophilized Method: Chromogenic Assay principle: Anti Xa Interferences: No interference of (UF heparin or LMW heparin) < 2 U/mL, α1-Antitrypsin < 2 mg/mL, α2-macroglobulin< 7 mg/mL, Heparin Cofactor II < 3 IU/mL, hemoglobin < 200 mg/dL, bilirubin < 20 mg/dL and triglycerides < 1000 mg/dL.
Werfen	HemosIL liquid Antithrombin	Werfen HemosIL liquid Antithrombin	Reagent: Liquid Method: Chromogenic Assay principle: Anti Xa Interferences: No interference of heparin (UF heparin or LMW heparin) < 4 U/mL, α1-Antitrypsin < 4 mg/mL, α2-macroglobulin < 7 mg/mL, Heparin Cofactor II < 4 U/mL, hemoglobin < 150 mg/dL, bilirubin < 40 mg/dL and triglycerides < 500 mg/dL.

ECAT

Antithrombin activity

ECAT Foundation

Direct links

Contact

Newsletter